Clinical Trial Update: A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials [Phase 2]

View source ↗

Summary

The Phase 2 study evaluating long-term Spesolimab in patients with fistulising Crohn's disease has been terminated, and trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Crohn Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-11-05